Drug intelligence / Profile preview

YanXinShi + trimetazidine

Development stage
Unknown
Lead developer
Qingdao Growful Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

YanXinShi + trimetazidine is a fixed-dose combination of two agents used in the management of cardiovascular diseases, particularly coronary heart disease (CHD) and heart failure. - **YanXinShi (Yangxinshi)** is a traditional Chinese medicine tablet composed of thirteen herbal ingredients, including Astragalus membranaceus, Codonopsis pilosula, Salvia miltiorrhiza, Pueraria, epimedium, hawthorn, Rehmannia glutinosa, angelica, Coptis chinensis, corydalis, Ganoderma lucidum, ginseng and licorice. It is widely used to improve exercise capacity and quality of life in patients with CHD and heart failure by reinforcing Qi and activating blood according to TCM theory. Mechanistically it has been shown to enhance myocardial mitochondrial function (increasing ATP production), promote mitochondrial biogenesis and aerobic metabolism in preclinical models[3]. - **Trimetazidine** is a small molecule antianginal agent that acts as a metabolic modulator; it improves myocardial glucose utilization through inhibition of fatty acid metabolism. This results in improved cardiac efficiency under ischemic conditions. The combination aims to synergistically improve cardiac energy metabolism—YanXinShi via multi-targeted herbal effects on mitochondria/oxidative stress/vascular function per TCM principles[3], and trimetazidine via direct metabolic modulation at the cellular level.

Other names
Yangxinshi + trimetazidine
02

Targets

HADHB (Long-chain 3-ketoacyl-CoA thiolase)

Beyond the preview

Go deeper on YanXinShi + trimetazidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on YanXinShi + trimetazidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call